Smokeless Tobacco Clinical Trial
Official title:
Human Laboratory Study of Smokeless Tobacco Products
With the advent of restrictions on public smoking, the tobacco industry has introduced a variety of novel smokeless tobacco products (NSTP) to allow continued tobacco use. These products typically have lower tobacco-specific nitrosamines, carcinogens and nicotine than conventional smokeless products out on the market. No studies have compared the effects of NSTP and medicinal nicotine products (MNP) in smokeless tobacco users and whether some of the NSTP products may serve as a cessation tool for smokeless tobacco users. Our hypothesis is that the effects from these products will be directly related to their nicotine content and sensory effects. Products that produce greater effects on outcome measures may serve as potential cessation tools.
Treatment will be a 3-period crossover study using Commit Nicotine Lozenge, Stonewall Disposable Tobacco Pieces and Camel Snus Frost Pouches. Each period will last 14 days with 11 days of product use and 1.5 days abstinence of all nicotine-containing products for a total of 10 weeks. Participants will begin the study by completing a baseline assessment on their own product, Skoal Wintergreen. ;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03998735 -
Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure
|
Phase 1 | |
Completed |
NCT00265681 -
Telephone Counseling for Snuff Users
|
N/A | |
Completed |
NCT01369693 -
In-vivo Extraction of Pb, Cd and TSNA From Swedish Snus
|
Phase 1 | |
Completed |
NCT01249339 -
In-vivo Extraction of Pb, Cd andTSNA From Swedish Snus
|
Phase 1 | |
Active, not recruiting |
NCT02994082 -
Treating Smokeless Tobacco Use in Rural Veterans
|
N/A | |
Completed |
NCT00414180 -
Bupropion SR for Treating Smokeless Tobacco Use
|
Phase 3 |